|
Substance active |
Pembrolizumab |
|
Holder |
MSD Belgium |
|
Status |
Running |
|
Indication |
treatment of resectable stage III-IVA locally advanced squamous head and neck carcinoma as neoadjuvant treatment, continued as adjuvant treatment in combination with radiation therapy with or without cisplatin and then as monotherapy in adults, whose tumours express PD L1 with a CPS ≥ 1. |
|
Public documents |
|
|
Last update |
28/08/2025 |
Keytruda
Last updated on